Fortical

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fortical

What is Fortical?

Fortical is a synthetic version of the hormone calcitonin, which is naturally produced by the thyroid gland in the human body. This medication is delivered as a nasal spray and is primarily used in the management of postmenopausal osteoporosis.

How Fortical Functions

Fortical works by mimicking the activity of endogenous calcitonin. Its primary biological role involves the regulation of calcium levels and bone metabolism. The medication interacts with specific receptors on osteoclasts, which are the cells responsible for breaking down bone tissue. By inhibiting the activity of these cells, Fortical helps to reduce the rate of bone resorption.

In addition to its effect on bone-resorbing cells, the medication influences how the kidneys handle minerals. It promotes the excretion of calcium, phosphate, and sodium through the urine, which contributes to the maintenance of mineral balance within the bloodstream.

Therapeutic Purpose

The goal of treatment with Fortical is to help preserve bone mass in women who are at least five years past menopause. By slowing the loss of bone density, the medication supports the structural integrity of the skeletal system in individuals with osteoporosis for whom other treatments may not be suitable or preferred.

Regulatory References

  1. NIH Review on Calcitonin and Bone Turnover

What side effects are possible with Fortical?

Fortical: Possible Side Effects and Safety Information

Fortical (calcitonin-salmon nasal spray) carries a defined safety profile, which includes common local effects, systemic adverse reactions, and serious safety warnings based on clinical data and regulatory documents.

Serious Safety Warnings

  • Malignancy Risk: Clinical trials suggest an increased risk of overall malignancies (cancers) in patients treated with calcitonin-salmon, compared to those receiving placebo. Due to this potential association, the need for continued therapy should be periodically re-evaluated.
  • Hypersensitivity Reactions: Serious reactions, including anaphylaxis and anaphylactic shock, have been reported. This medication is contraindicated in patients with known hypersensitivity to calcitonin-salmon or any of its excipients. Skin testing may be considered for patients with suspected sensitivity prior to use.
  • Hypocalcemia: Low calcium levels in the blood have been reported and can lead to symptoms such as muscle cramps, twitching (tetany), and seizures. Pre-existing hypocalcemia must be corrected before starting therapy.

Common and Local Adverse Reactions

The most commonly reported adverse reactions (mathbf3% or greater incidence) are primarily related to the nasal route of administration and general discomfort:

  • Nasal Symptoms: Includes rhinitis (runny nose), epistaxis (nosebleeds), nasal irritation, dryness, and crusting.
  • Systemic Complaints: Headache, back pain, and arthralgia (joint pain) are also frequently reported.

Other Safety Considerations

  • Nasal Monitoring: Periodic nasal examinations are recommended due to the potential for nasal adverse reactions, including severe ulceration. The drug should be discontinued if severe nasal ulceration occurs.
  • Population Use: Safety and efficacy have not been established in the pediatric population. It is not known if the drug is excreted in human milk.
  • Calcium and Vitamin D: Adequate intake of calcium and Vitamin D is generally recommended in conjunction with this therapy.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The official overdose profile for Calcitonin Salmon (Fortical) is based on reports of exacerbated pharmacological effects and severe systemic reactions, as documented in regulatory information.

Feature Regulatory Content (Official Labeling)
Documented Overdose Manifestations Symptoms following large doses are often dose-dependent, including nausea, vomiting, dizziness, and facial flushing.
Severe Outcomes Life-threatening reactions, such as anaphylaxis and anaphylactic shock, have been reported with calcitonin, necessitating immediate emergency protocols.
Immediate Help Required For Signs of a severe allergic reaction, including bronchospasm or swelling of the tongue or throat. The usual provisions for emergency treatment must be made available.
Management and Antidote No specific antidote is known, and the required procedure is symptomatic and supportive treatment. The patient must be maintained under observation following a suspected overdose.

In overdose situations, the physiological risk includes a severe, transient decrease in calcemia, which may be associated with tetany and seizure activity; the label requires provisions for parenteral calcium to manage this risk. This information structures the mandatory emergency response, focusing on the immediate management of both dose-related symptoms and severe systemic complications.

Therapeutic Uses of Fortical

Quick Facts

  • Condition Managed: Postmenopausal osteoporosis in women
  • Therapeutic Role: Used when other treatments are not suitable
  • Objective: To assist in the management of bone mineral density losses

Fortical (calcitonin salmon) is a therapeutic option indicated for the management of postmenopausal osteoporosis. The use of this medication is reserved for women who are at least five years past menopause and for whom alternative treatments are not suitable or appropriate.

The principal objective of treatment is to help maintain bone mineral density and address the progressive loss of bone mass that characterizes the condition. Calcitonin salmon is associated with a reduced risk of new vertebral fractures; however, its effectiveness in preventing non-vertebral or hip fractures has not been established.

Patients using this therapy are recommended to maintain adequate intake of calcium and Vitamin D as part of a complete management plan. The use of this medication is specifically limited to the population and conditions described.

Eligibility and Restrictions for Use

The eligibility profile for Fortical (calcitonin salmon nasal spray) is strictly defined by regulatory bodies. The medication is generally reserved for women greater than five years postmenopause for whom alternative treatments are not suitable.

The absolute non-eligibility rule is established by a known hypersensitivity to calcitonin salmon or any component of the formulation, which constitutes a formal contraindication.

Eligibility is highly conditional. Before starting therapy, two metabolic conditions must be corrected: low calcium levels (hypocalcemia) and Vitamin D deficiency. Use must be discontinued if severe ulceration of the nasal mucosa occurs, and the need for continued, long-term therapy requires periodic re-evaluation.

Eligibility Limitation Status
Pediatric Use Safety and effectiveness not established.
Pregnancy/Lactation Not indicated for females of reproductive potential.
European Union Indication for osteoporosis is no longer authorized in the region.

Fortical is not recommended for use in children, and older adult patients (65 and over) should be monitored due to the more frequent occurrence of adverse nasal effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Fortical (calcitonin salmon) nasal spray indicates that dedicated formal drug interaction studies have not been widely conducted; however, specific interactions, mandatory use restrictions, and procedural constraints are defined.

Documented Interactions and Outcomes:

Interacting Substance Official Interaction Statement Outcome Classification
Lithium Co-administration may lead to a reduction in plasma lithium concentrations. This is attributed to an increased urinary clearance of lithium. Exposure Reduction
Diphosphonates (Prior Use) Prior use in patients with Paget's disease is noted to reduce the expected anti-resorptive response to calcitonin salmon. Response Modification
Calcium and Vitamin D Adequate intake of both supplements is a mandatory co-requirement recommended in conjunction with therapy. Procedural Constraint

Interaction-Related Restrictions

Use of this medicine is contraindicated in individuals with a known hypersensitivity to the active substance or any product excipients. Additionally, the metabolic condition of Hypocalcemia must be corrected before the initiation of therapy, serving as a mandatory precondition. The regulatory labeling does not specify any timing-separation rules requiring doses of co-administered medicines to be spaced apart.

Mechanism of Action

How Fortical Works

Fortical (calcitonin-salmon) is a polypeptide that functions as an agonist by binding with high affinity to the specific calcitonin receptor. This receptor is primarily expressed on the surface of osteoclasts (bone-resorbing cells) and in the renal tubules of the kidney, allowing for a multifaceted pharmacodynamic effect.

In bone, receptor binding immediately initiates an inhibitory molecular cascade involving cyclic adenosine monophosphate (cAMP), leading to the rapid arrest of osteoclast activity. This action modulates the signaling sequence that drives bone breakdown, restricting the rate of osteoclast-mediated bone resorption and modifying the physiological balance between bone resorption and formation.

In the kidney, receptor activation modifies early molecular steps governing mineral transport. This promotes the urinary excretion of both calcium and phosphate, which influences circulating levels of these minerals. Additionally, the drug engages specific receptors within the central nervous system (CNS) pain-processing regions, initiating signal modification that alters the transmission of pain-related neural impulses.

Dosage and Administration Information

How Fortical is Used: Official Administration Guidelines

Fortical (calcitonin salmon) is formulated as a metered-dose solution and is administered strictly via the intranasal route. The medication is provided in a specialized spray device designed to ensure a consistent dose is delivered per actuation.


Official Dosing and Frequency

The standard prescribed dose for the management of postmenopausal bone mineral density loss is 200 International Units (IU), delivered as one spray once daily. There are no dosage adjustments for older adults or those with renal or hepatic impairment.

Administration Detail Official Instruction
Dose 200 IU (One Spray)
Frequency Once Daily
Nostril Use Alternate nostrils daily

Administration Requirements and Protocol

Before initial use, the unopened bottle must be allowed to reach room temperature. The device must then be primed by activating the pump at least five times until a full spray is produced; priming is not required before subsequent daily doses.

Proper use requires administering the dose into alternating nostrils daily to promote absorption and minimize local effects. The therapy is maintained in conjunction with supplemental intake of at least 1000 mg of elemental calcium and 400 IU of Vitamin D daily. A component of the usage protocol involves discarding the bottle after 30 doses, regardless of any remaining contents, to ensure accurate dosing over time. The overall treatment course is generally long-term, and the need for continued therapy is re-evaluated periodically by a healthcare provider.

Recent Clinical Evidence

Fortical: Recent Clinical Evidence

This section summarizes the published research regarding the clinical use of calcitonin salmon nasal spray (Fortical), focusing on what has been evaluated in studies and what remains uncertain.


Evidence for use in Postmenopausal Osteoporosis

Research examined the use of this medicine in postmenopausal women with established bone density loss, primarily through large-scale, placebo-controlled trials lasting up to five years. The research evaluated two main endpoints: the occurrence of new spinal (vertebral) fractures and changes in Bone Mineral Density (BMD) in the spine.

Findings describe patterns observed in the studies regarding a difference in the incidence of new vertebral fractures between the study group and the comparison group over the observation period. Studies also reported measurements of changes in BMD in the spine. However, the available evidence is not conclusive regarding the effect on non-vertebral fractures, such as those occurring at the hip, and certainty remains low for those outcomes.


Evidence for the Analgesic Role in Acute Fractures

Research has also explored whether this medicine was associated with outcomes related to physical discomfort immediately following an acute spinal fracture. This evidence was gathered from short-term, placebo-controlled trials. The main outcomes monitored were patient-reported measurements of pain intensity and the consumption of additional pain medication during periods of heightened symptom activity.

Some findings describe patterns where pain intensity was measured differently across study and placebo groups in the acute phase. However, these results are strictly limited to short-term symptom changes, and long-term outcomes are not well characterized for this specific use.

Key Studies & References Efficacy of calcitonin for treating acute pain associated with osteoporotic vertebral compression fracture: an updated systematic review

Frequently Asked Questions (FAQ)

Common questions about Fortical (FAQ)


Q: What happens if I miss a day of using Fortical?

A: Official patient guidance describes administering a missed dose as soon as it is remembered. However, if it is almost time for the next scheduled spray, it is suggested to skip the missed dose and resume the regular schedule. The guidance is not to use two sprays in a single administration to compensate for a missed dose.

Q: Is Fortical only for preventing bone loss, or can it help rebuild bone?

A: Regulatory documents classify this medicine as a bone metabolism regulator whose primary effect is to inhibit the breakdown of bone, known as bone resorption. By slowing down this process, it helps preserve existing bone mass. Clinical studies also reported measurements of changes in bone mineral density (BMD) in the spine.

Q: Does the efficacy of Fortical decrease over time?

A: Official product information notes that in some patients, circulating antibodies to calcitonin salmon may develop over the course of treatment. This development may be associated with a loss of response to the therapy.

Q: Why do official documents mention possible malignancy with Fortical use?

A: Regulatory documents include a warning about a potential increased risk of overall cancer (malignancy). This information is based on an analysis of data collected from 21 controlled clinical trials involving patients treated with calcitonin salmon.

Q: Are there common skin reactions associated with Fortical?

A: While the most common adverse reactions listed in the documentation are nasal symptoms, post-marketing reports have included systemic skin-related reactions. These reactions may include rash (dermatitis), increased sweating, or itchiness (pruritus).

Q: Can Fortical affect my ability to drive or operate machinery?

A: Post-marketing patient reports have included nervous system issues, such as dizziness or seizure. If a patient experiences such reactions, they are advised to use caution when performing tasks that require full attention, like driving or operating machinery.

Q: What is Paget's disease, and why is Fortical sometimes used for it?

A: Paget's disease of bone is described as a moderate to severe condition involving elevated bone turnover markers. Calcitonin salmon is reserved for use when alternative treatments are not suitable.

Q: Can Fortical be used by people with kidney problems?

A: Although the regulatory labeling specifies no need for dosage adjustments in patients with kidney problems, the medicine is primarily broken down in the kidneys. Its metabolic clearance may therefore be reduced in patients with end-stage renal failure.

Q: Is Fortical the same as other calcitonin nasal sprays?

A: The active ingredient in Fortical is calcitonin salmon. This substance is the same active ingredient found in other nasal sprays belonging to the calcitonin class of medicines.

Q: Can men use Fortical for bone density issues?

A: The medication is specifically indicated for the treatment of postmenopausal osteoporosis, meaning it is reserved for women who are at least five years past menopause. It is generally not indicated for use in men.

Q: How quickly does Fortical start to affect bone health?

A: Clinical studies that monitored changes in bone mineral density (BMD) of the spine reported statistically significant changes when compared to a placebo. These differences were measurable as early as six months after the treatment was started.

Q: Is Fortical meant for short-term or long-term use?

A: Due to a possible link with an increased risk of malignancy (cancer) observed in clinical trials, the regulatory labeling suggests that the need for continued, long-term therapy should be re-evaluated periodically by a healthcare provider.

Q: Can Fortical change my sense of taste or smell?

A: The official product documentation notes that loss of taste or smell has been reported by patients as a special senses-related adverse reaction during the period after the medicine was approved for use.

Q: Does the package insert mention any specific food to avoid while using Fortical?

A: The package insert does not list any specific foods that must be avoided while using this medication. However, it recommends that adequate daily intake of both elemental calcium and Vitamin D be maintained in conjunction with this therapy.

Q: Can using Fortical cause pain in the joints?

A: Joint pain, medically known as arthralgia, is listed in the regulatory documents as one of the most commonly reported adverse reactions. Its incidence was reported to be 3% or greater in clinical trials.

Q: Is there a generic version of Fortical available?

A: The active ingredient in this product, calcitonin salmon nasal spray, is available in generic formulations. The Fortical brand-name product itself has been discontinued in some regions.

Q: Does Fortical contain any preservatives?

A: The formulation contains several inactive ingredients, including Phenylethyl Alcohol and Benzyl Alcohol. These substances are included in the medicine and are commonly used as preservatives.

Q: Are there warnings about using Fortical with lithium?

A: The official drug interaction document notes that using this medicine along with lithium may result in reduced levels of lithium in the blood. This effect is attributed to an increased clearance of lithium by the kidneys.

Q: What is the role of Fortical after a bone fracture?

A: Clinical research has investigated the medicine's use in the acute phase immediately following a spinal fracture. The focus of these studies was specifically on its potential association with outcomes related to patient-reported physical discomfort.

Q: Is it true that calcitonin is naturally produced in the body?

A: Calcitonin is indeed a hormone that occurs naturally in the human body, where it plays a role in calcium regulation. The medicine contains a synthetic version of the calcitonin found in salmon, which is structurally similar to the human hormone.

Q: How does Fortical affect the balance of minerals in the body?

A: In the kidney, the medicine acts to modify the process of mineral transport. This action promotes the urinary excretion of both calcium and phosphate, which influences the circulating levels of these minerals in the body.

Q: If I have mild asthma, can I still use Fortical?

A: Post-marketing reports have included serious allergic-type reactions, such as bronchospasm, which is the sudden tightening of the airways. This is listed as a respiratory-related adverse reaction.

Q: What does the manufacturer say about traveling with Fortical?

A: The official documentation provides detailed storage rules that apply, including while traveling. Unopened bottles should be refrigerated, while opened bottles must be stored at room temperature, and freezing should always be avoided.

How should Fortical be stored and disposed of?

Storage and Disposal of Fortical

The storage requirements for Fortical (calcitonin-salmon) Nasal Spray are distinct for unopened and opened bottles, and both must be kept out of the reach of children.


Storage Conditions

Product State Temperature Requirement Handling Rule
Unopened Bottle Store in a refrigerator (36 F to 46 F) Protect from freezing and allow to reach room temperature before first use.
Opened Bottle Store at room temperature (68 F to 77 F) Store in an upright position; do not return to the refrigerator.

Stability and Disposal

Once assembled and primed, the bottle must be discarded after 30 days or after 30 doses have been used, whichever comes first. The medicine is not recommended for flushing down the toilet or sink. Dispose of the unused or expired product through a drug take-back program or according to household trash guidelines after mixing it with an undesirable substance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fortical found in:

A-Z Index: